Randomized, Phase II Study Comparing Interferon Combined with Hepatic Arterial Infusion of Fluorouracil plus Cisplatin and Fluorouracil Alone in Patients with Advanced Hepatocellular Carcinoma
スポンサーリンク
概要
- 論文の詳細を見る
Objective: This randomized phase II trial compared the response rates to treatment with interferon (IFN) combined with hepatic arterial infusion of fluorouracil (FU) plus cisplatin (CDDP) or FU alone in patients with advanced hepatocellular carcinoma (HCC). Methods: A total of 114 patients with measurable advanced HCC were enrolled and randomized into 2 groups. FU (300 mg/m2, days 1–5, days 8–12) with or without CDDP (20 mg/m2, days 1 and 8) was administered via the hepatic artery. IFNα-2b was administered 3 times per week for 4 weeks. Results: The response rates were 45.6% for the IFN/FU + CDDP group and 24.6% for the IFN/FU group. The response rate was significantly higher in the IFN/FU + CDDP group (p = 0.030). The median overall survival period was 17.6 months in the IFN/FU + CDDP group versus 10.5 months in the IFN/FU group (p = 0.522). The median progression-free survival period was 6.5 months in the IFN/FU + CDDP group versus 3.3 months in the IFN/FU group (p = 0.0048). Hematological toxicity was common, but no toxicity-related deaths were observed. Conclusion: These results show the clinical efficacy of adding CDDP to the hepatic arterial infusion of FU in combined chemotherapy regimens with IFN.
- 2011-11-30
論文 | ランダム
- 組織適合抗原 (比較生物学-2-) -- (防御と免疫)
- 組織適合抗原の遺伝--H-2 complexの遺伝的構造 (免疫) -- (移植と癌)
- 編集長VISITING(238)抗菌薬の適正使用 キーワードはPK/PDパラメーター--"理論的投与法"こそ"理想的投与法"--川崎医科大学呼吸器内科講師 二木芳人氏
- ファジィ理論に基づく美観を考慮した橋梁設計に関する一考察
- コスト最小規準によるPC斜張橋の最適斜材張力決定法に関する研究